- Home
- MRM vs ADXN Comparison
MRM vs ADXN Comparison
Compare MRM & ADXN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MRM | ADXN |
|---|---|---|
| Founded | 2000 | 2002 |
| Country | Japan | Switzerland |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.3M | 8.6M |
| IPO Year | 2020 | 2019 |
Fundamental Metrics
Financial Performance| Metric | MRM | ADXN |
|---|---|---|
| Price | $0.99 | $6.34 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 22.0K | 4.6K |
| Earning Date | 05-19-2026 | 04-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $86.57 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $32.01 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.90 | $5.41 |
| 52 Week High | $4.45 | $12.05 |
Technical Indicators
Market Signals| Indicator | MRM | ADXN |
|---|---|---|
| Relative Strength Index (RSI) | 38.98 | 43.03 |
| Support Level | N/A | $5.75 |
| Resistance Level | $1.31 | $7.37 |
| Average True Range (ATR) | 0.10 | 0.46 |
| MACD | -0.02 | -0.03 |
| Stochastic Oscillator | 4.44 | 19.05 |
Price Performance
Historical ComparisonAbout MRM MEDIROM Healthcare Technologies Inc.
MEDIROM Healthcare Technologies Inc provides health services. The company is a franchiser and operator of healthcare salons and operates in segments namely Relaxation Salon, Digital Preventative Healthcare, and Luxury Beauty Segment. The company generates a majority of its revenue from the Relaxation Salon business segment. Geographically, the company generates a maximum share of its revenue from Japan.
About ADXN Addex Therapeutics Ltd
Addex Therapeutics Ltd is a clinical-stage biopharmaceutical company. The company is focused on the development and commercialization of an emerging class of novel orally available small-molecule drugs known as allosteric modulators. The company's geographical area of operations includes Switzerland and Europe. The Company operates in one segment, which is the discovery, development, and commercialization of small-molecule pharmaceutical products.